Integral Interest Expense vs Selling General Administrative Analysis

IDX Stock

2.91 0.01 0.34%

Integral Diagnostics financial indicator trend analysis is infinitely more than just investigating Integral Diagnostics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Integral Diagnostics is a good investment. Please check the relationship between Integral Diagnostics Interest Expense and its Selling General Administrative accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integral Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Interest Expense vs Selling General Administrative

Interest Expense vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Integral Diagnostics Interest Expense account and Selling General Administrative. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Integral Diagnostics' Interest Expense and Selling General Administrative is 0.82. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Integral Diagnostics, assuming nothing else is changed. The correlation between historical values of Integral Diagnostics' Interest Expense and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Integral Diagnostics are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Interest Expense i.e., Integral Diagnostics' Interest Expense and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Selling General Administrative

Most indicators from Integral Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Integral Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integral Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to drop to about 162.8 M in 2024. Tax Provision is likely to drop to about 3.4 M in 2024

	2021	2022	2023	2024 (projected)
Operating Income	38.4M	40.1M	5.4M	5.1M
Total Revenue	358.7M	440.1M	469.7M	238.8M

Operating Income Total Revenue

Integral Diagnostics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Net Receivables	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Liab	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets	Short Term Debt	Other Liab	Net Tangible Assets	Long Term Debt	Non Current Liabilities Total	Other Current Assets	Deferred Long Term Liab
Total Assets		0.97	0.99	0.44	0.87	1.0	0.92	1.0	0.94	0.9	0.92	0.8	1.0	-0.65	0.75	0.8	0.84	-0.92	0.89	0.88	0.9	-0.8	0.99	0.99	0.81	-0.22
Total Current Liabilities	0.97		0.95	0.41	0.84	0.98	0.89	0.97	0.98	0.87	0.91	0.78	0.97	-0.65	0.72	0.78	0.86	-0.87	0.87	0.94	0.9	-0.84	0.96	0.95	0.82	-0.23
Total Stockholder Equity	0.99	0.95		0.46	0.87	0.98	0.92	0.98	0.92	0.89	0.93	0.81	0.99	-0.65	0.76	0.81	0.84	-0.92	0.89	0.87	0.89	-0.76	0.98	0.98	0.79	-0.2
Retained Earnings	0.44	0.41	0.46		0.06	0.42	0.16	0.39	0.35	0.17	0.29	0.45	0.41	-0.89	0.9	0.45	0.39	-0.19	0.45	0.47	0.16	-0.21	0.38	0.38	0.52	0.63
Net Receivables	0.87	0.84	0.87	0.06		0.86	0.99	0.88	0.85	0.94	0.89	0.69	0.88	-0.29	0.44	0.69	0.77	-0.94	0.78	0.73	0.97	-0.79	0.89	0.88	0.67	-0.63
Total Liab	1.0	0.98	0.98	0.42	0.86		0.91	1.0	0.95	0.9	0.9	0.79	1.0	-0.64	0.74	0.79	0.83	-0.92	0.88	0.89	0.91	-0.83	0.99	0.99	0.81	-0.22
Common Stock	0.92	0.89	0.92	0.16	0.99	0.91		0.92	0.88	0.97	0.9	0.74	0.93	-0.41	0.53	0.74	0.82	-0.96	0.83	0.81	0.98	-0.8	0.93	0.92	0.73	-0.56
Short Long Term Debt Total	1.0	0.97	0.98	0.39	0.88	1.0	0.92		0.94	0.92	0.9	0.79	1.0	-0.61	0.72	0.79	0.83	-0.93	0.88	0.88	0.92	-0.83	0.99	1.0	0.8	-0.26
Other Current Liab	0.94	0.98	0.92	0.35	0.85	0.95	0.88	0.94		0.83	0.91	0.75	0.94	-0.58	0.69	0.75	0.81	-0.85	0.83	0.9	0.89	-0.83	0.93	0.92	0.78	-0.27
Net Debt	0.9	0.87	0.89	0.17	0.94	0.9	0.97	0.92	0.83		0.83	0.64	0.92	-0.41	0.53	0.64	0.79	-0.95	0.74	0.79	0.98	-0.86	0.92	0.92	0.67	-0.57
Accounts Payable	0.92	0.91	0.93	0.29	0.89	0.9	0.9	0.9	0.91	0.83		0.67	0.92	-0.5	0.59	0.67	0.88	-0.83	0.78	0.8	0.86	-0.76	0.91	0.88	0.64	-0.3
Cash	0.8	0.78	0.81	0.45	0.69	0.79	0.74	0.79	0.75	0.64	0.67		0.76	-0.59	0.7	1.0	0.67	-0.75	0.99	0.77	0.7	-0.44	0.79	0.79	0.95	-0.11
Non Current Assets Total	1.0	0.97	0.99	0.41	0.88	1.0	0.93	1.0	0.94	0.92	0.92	0.76		-0.62	0.73	0.76	0.84	-0.93	0.85	0.87	0.91	-0.83	0.99	0.99	0.77	-0.25
Non Currrent Assets Other	-0.65	-0.65	-0.65	-0.89	-0.29	-0.64	-0.41	-0.61	-0.58	-0.41	-0.5	-0.59	-0.62		-0.93	-0.59	-0.59	0.42	-0.62	-0.72	-0.41	0.48	-0.6	-0.6	-0.67	-0.41
Other Assets	0.75	0.72	0.76	0.9	0.44	0.74	0.53	0.72	0.69	0.53	0.59	0.7	0.73	-0.93		0.7	0.58	-0.58	0.74	0.73	0.53	-0.51	0.71	0.72	0.75	0.32
Cash And Short Term Investments	0.8	0.78	0.81	0.45	0.69	0.79	0.74	0.79	0.75	0.64	0.67	1.0	0.76	-0.59	0.7		0.67	-0.75	0.99	0.77	0.7	-0.44	0.79	0.79	0.95	-0.11
Common Stock Shares Outstanding	0.84	0.86	0.84	0.39	0.77	0.83	0.82	0.83	0.81	0.79	0.88	0.67	0.84	-0.59	0.58	0.67		-0.7	0.75	0.86	0.82	-0.75	0.83	0.78	0.73	-0.26
Other Stockholder Equity	-0.92	-0.87	-0.92	-0.19	-0.94	-0.92	-0.96	-0.93	-0.85	-0.95	-0.83	-0.75	-0.93	0.42	-0.58	-0.75	-0.7		-0.83	-0.77	-0.93	0.76	-0.92	-0.95	-0.72	0.47
Total Current Assets	0.89	0.87	0.89	0.45	0.78	0.88	0.83	0.88	0.83	0.74	0.78	0.99	0.85	-0.62	0.74	0.99	0.75	-0.83		0.83	0.79	-0.55	0.88	0.87	0.95	-0.16
Short Term Debt	0.88	0.94	0.87	0.47	0.73	0.89	0.81	0.88	0.9	0.79	0.8	0.77	0.87	-0.72	0.73	0.77	0.86	-0.77	0.83		0.84	-0.73	0.86	0.85	0.85	-0.2
Other Liab	0.9	0.9	0.89	0.16	0.97	0.91	0.98	0.92	0.89	0.98	0.86	0.7	0.91	-0.41	0.53	0.7	0.82	-0.93	0.79	0.84		-0.87	0.93	0.91	0.74	-0.58
Net Tangible Assets	-0.8	-0.84	-0.76	-0.21	-0.79	-0.83	-0.8	-0.83	-0.83	-0.86	-0.76	-0.44	-0.83	0.48	-0.51	-0.44	-0.75	0.76	-0.55	-0.73	-0.87		-0.85	-0.82	-0.57	0.43
Long Term Debt	0.99	0.96	0.98	0.38	0.89	0.99	0.93	0.99	0.93	0.92	0.91	0.79	0.99	-0.6	0.71	0.79	0.83	-0.92	0.88	0.86	0.93	-0.85		0.99	0.81	-0.28
Non Current Liabilities Total	0.99	0.95	0.98	0.38	0.88	0.99	0.92	1.0	0.92	0.92	0.88	0.79	0.99	-0.6	0.72	0.79	0.78	-0.95	0.87	0.85	0.91	-0.82	0.99		0.79	-0.27
Other Current Assets	0.81	0.82	0.79	0.52	0.67	0.81	0.73	0.8	0.78	0.67	0.64	0.95	0.77	-0.67	0.75	0.95	0.73	-0.72	0.95	0.85	0.74	-0.57	0.81	0.79		-0.12
Deferred Long Term Liab	-0.22	-0.23	-0.2	0.63	-0.63	-0.22	-0.56	-0.26	-0.27	-0.57	-0.3	-0.11	-0.25	-0.41	0.32	-0.11	-0.26	0.47	-0.16	-0.2	-0.58	0.43	-0.28	-0.27	-0.12

Click cells to compare fundamentals

Integral Diagnostics Account Relationship Matchups

Integral Diagnostics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	586.9M	654.9M	783.0M	839.0M	744.3M	394.3M
Total Current Liabilities	76.8M	78.4M	80.6M	83.5M	87.1M	49.0M
Total Stockholder Equity	228.3M	254.7M	347.2M	373.0M	301.7M	165.0M
Retained Earnings	31.7M	44.4M	37.2M	49.6M	(25.0M)	(23.7M)
Net Receivables	10.4M	15.8M	24.3M	23.9M	27.2M	28.5M
Total Liab	358.6M	400.2M	435.8M	466.0M	442.6M	229.3M
Common Stock	207.4M	219.2M	322.5M	333.3M	335.0M	351.8M
Short Long Term Debt Total	277.8M	308.4M	341.0M	365.1M	357.8M	190.3M
Other Current Liab	43.3M	51.7M	54.1M	55.6M	59.3M	35.3M
Net Debt	219.9M	246.2M	217.8M	331.2M	315.4M	331.1M
Accounts Payable	4.6M	4.8M	8.7M	10.4M	10.2M	5.4M
Cash	58.0M	62.2M	123.2M	33.9M	42.4M	38.5M
Non Current Assets Total	507.1M	568.5M	624.8M	770.6M	669.5M	368.3M
Non Currrent Assets Other	(496.8M)	(315.8M)	(352.5M)	(444.5M)	25.7M	27.0M
Other Assets	13.6M	16.3M	17.3M	19.0M	1.0	0.95
Cash And Short Term Investments	58.0M	62.2M	123.2M	33.9M	42.4M	38.5M
Liabilities And Stockholders Equity	586.9M	654.9M	783.0M	839.0M	744.3M	427.1M
Other Stockholder Equity	(239.1M)	(263.6M)	(359.7M)	(382.8M)	(344.6M)	(327.3M)
Total Current Assets	79.8M	86.4M	158.2M	68.4M	74.8M	56.3M
Accumulated Other Comprehensive Income	(10.8M)	(8.9M)	(12.5M)	(9.8M)	(8.3M)	(8.7M)
Short Term Debt	22.8M	17.0M	17.2M	16.7M	16.2M	12.6M
Other Liab	27.3M	30.9M	32.0M	34.9M	40.1M	42.1M
Net Tangible Assets	(72.5M)	(90.0M)	(33.2M)	(101.7M)	(91.6M)	(87.0M)
Long Term Debt	157.0M	192.2M	217.6M	221.1M	219.8M	131.6M
Non Current Liabilities Total	281.8M	321.7M	355.2M	382.4M	356.9M	200.7M
Other Current Assets	6.4M	7.4M	9.4M	3.2M	3.6M	4.3M
Short Long Term Debt	13.2M	6.5M	5.5M	2.5M	2.2M	2.1M
Property Plant And Equipment Net	189.6M	211.5M	231.1M	282.5M	270.4M	159.0M
Current Deferred Revenue	5.5M	5.0M	602K	871K	1.5M	1.5M
Good Will	280.0M	315.8M	352.5M	444.5M	373.3M	255.7M
Long Term Debt Total	255.1M	291.4M	323.8M	348.4M	400.7M	420.7M
Inventory	1.0M	914K	1.3M	1.8M	1.7M	895.5K
Property Plant And Equipment Gross	189.6M	287.5M	326.1M	385.3M	400.4M	203.4M
Intangible Assets	307.3M	344.7M	380.5M	474.8M	25.7M	24.4M
Property Plant Equipment	189.6M	211.5M	231.1M	282.5M	324.8M	341.1M
Short Term Investments	296K	401K	345K	381K	438.2K	269.2K
Capital Lease Obligations	96.1M	109.6M	117.9M	141.5M	135.8M	85.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integral Stock Analysis

When running Integral Diagnostics' price analysis, check to measure Integral Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integral Diagnostics is operating at the current time. Most of Integral Diagnostics' value examination focuses on studying past and present price action to predict the probability of Integral Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integral Diagnostics' price. Additionally, you may evaluate how the addition of Integral Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC